Navigation Links
Insmed Announces Fourth Quarter and Full-Year 2010 Financial Results
Date:3/10/2011

RICHMOND, Va., March 10, 2011 /PRNewswire/ -- Insmed Inc. (Nasdaq CM: INSMD), a biopharmaceutical company, today reported results for the fourth quarter and full-year ended December 31, 2010.

Key Recent Highlights:

  • Filed Investigational New Drug (IND) Application in February 2011 with the FDA to begin a phase 3 clinical trial for ARIKACE™ (liposomal amikacin for inhalation) in non-TB Mycobacteria (NTM) lung infections.
  • Successfully concluded 72 week phase 2b open-label study for ARIKACE for pseudomonas lung infections in cystic fibrosis (CF) patients.
  • Received positive opinion from European Medicines Agency (EMA) on Company's Pediatric Investigation Plan for ARIKACE in the CF indication.
  • Gained shareholder approval for conversion of preferred stock into common stock and 1:10 reverse stock split.

  • "Following the closure of our transformative business combination in December 2010, we have been aggressively moving forward with the development plan for ARIKACE, our phase 3 compound for pseudomonas lung infections for CF patients, and NTM lung infections," said Timothy Whitten, Insmed's President & CEO.  "We are well underway with the initial preparations and necessary work around these trials and continue to expect to begin accruing patients to the phase 3 trials in both indications in the second half of 2011, with results expected in the first half of 2013."

    Financial ResultsOn March 1, 2011, at a special meeting, our shareholders approved a one for 10 reverse stock split of our common stock, which became effective at 5:00 pm EST on March 2, 2011.  This reverse stock split is reflected in the shares outstanding and earnings per share calculations below.  

    Revenues for the fourth quarter ended December 31, 2010 were $1.3 million, as compared to $2.5 million for the corresponding period in 2009.  The $1.2 million decrease resulted from $0.6 million in lower cost r
    '/>"/>

    SOURCE Insmed Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Insmed to Host Second Quarter 2009 Conference Call
    2. Insmed Announces Addition to the Russell 3000(R) Index
    3. Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy
    4. Insmed CEO Resigns Due to Health Concerns
    5. Insmed Announces First Quarter 2009 Financial Results
    6. Insmed Regains NASDAQ Compliance
    7. Insmed to Host First Quarter 2009 Conference Call
    8. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
    9. Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
    10. Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
    11. Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/27/2014)... The “Molecular Diagnostic Market by ... INAAT, DNA Sequencing), End User (Hospital, Laboratories), & ... Forecast to 2018” provides a detailed overview of ... trends, and strategies impacting the global molecular diagnostics ... the revenue and share analysis. , The global ...
    (Date:10/27/2014)... 27, 2014 Called the NOAH ... eliminating several types of pediatric brain cancer. The ... in over 30 years of research and development. ... proves that one mom's determination can make a ... Halloween trick-or-treating, and it’s only fitting that we’ve ...
    (Date:10/27/2014)... , Oct. 27, 2014 Pressure BioSciences, ... worldwide leader in the development and sale of ... sciences research market, today announced that Professor ... novel, accurate, highly reproducible, and robust method to ... high-throughput protein analysis on small needle biopsy samples ...
    (Date:10/27/2014)... Investor-Edge has initiated coverage on ... NBIX ), Insmed Inc. (NASDAQ: INSM ), ... Corporation (NASDAQ: DYAX ), and Oncothyreon Inc. ... be accessed at: http://investor-edge.com/register . On ... 4,483.72, up 0.69%, the Dow Jones Industrial Average advanced ...
    Breaking Biology Technology:Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 2Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 3Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 4Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 5FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 2Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 4Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 5Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5
    ... - Strong R&D investments, especially in EHT Dx21 and EHT 0202 clinical, ... achieved for EHT Dx21, - Start of Phase IIa ... collaboration with Allergan and extension, until end 2011, ... Board, - New positioning of Genomic Services and of the SpliceArray(TM) ...
    ... in prominence as viable vehicle and jet fuel feedstockGREAT ... and researchers of camelina have formed the first trade ... America. The North American Camelina Trade Association (NACTA) ... of new markets for camelina - a relatively new ...
    ... Rates Under 1 Percent Since 2000,Partnership Will Target Acceleration and Commercialization ... ... Philippines (vocus) March 3, 2009 -- DuPont and the ... to boost rice yields. The Scientific Know-How and Exchange Program ...
    Cached Biology Technology:ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 2ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 3ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 4ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 5ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 6ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 7ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 8ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 9ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 10ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results 11New Trade Association Formed for North America Camelina Industry 2New Trade Association Formed for North America Camelina Industry 3DuPont and International Rice Research Institute Partner to Boost Rice Yields 2DuPont and International Rice Research Institute Partner to Boost Rice Yields 3
    (Date:10/29/2014)... City on September 19, 2014, leading geneticist and humanitarian ... Genome Sciences and Medicine at the University of Washington ... Tel Aviv University, was awarded the 2014 Lasker-Koshland Special ... her honorary degree from TAU, Prof. King was the ... and for the past 18 years she has been ...
    (Date:10/29/2014)... reveals new research potential of the Barcode of ... in the Biodiversity Data Journal ... format and imported these into a human-readable text developed ... (PWT). Data were used to study the species distributions ... Microgastrinae subfamily. , BOLD is originally designed to support ...
    (Date:10/29/2014)... international Cancer Genomics of the Kidney consortium ( ... cancer and exposure to aristolochic acid, an ingredient ... Nature Communications , have important implications for ... 140,000 people every year, and in Central Europe ... of the International Cancer Genome Consortium (ICGC), has ...
    Breaking Biology News(10 mins):Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2Kidney cancer in Central Europe 2
    ... (June 28 2013) A study carried out in India ... bone marrow stem cells in patients with type 2 ... when compared to a control group of TD2M patients ... , The study appears as an early e-publication for ...
    ... make a big difference. A "left-handed" molecule of a ... its mirror-image "right-handed" counterpart could be completely inactive. That,s ... crucial: Living organisms are made only from left-handed amino ... Now, a team of scientists at the U.S. ...
    ... the late spring, the 4000 elk of the Clarks ... following the greening grass into the highlands of the ... on vegetation fed by snowmelt. It,s a short trip ... uncommonly free of roads, fences, metropolitan areas, and other ...
    Cached Biology News:Type 2 diabetes patients transplanted with own bone marrow stem cells reduces insulin use 2Tiny nanocubes help scientists tell left from right 2Tiny nanocubes help scientists tell left from right 3Declining fortunes of Yellowstone's migratory elk 2Declining fortunes of Yellowstone's migratory elk 3Declining fortunes of Yellowstone's migratory elk 4
    Vitellogenin (Japanese medaka) Standard...
    nuclear RNA export factor 1, mRNA...
    ... analysis of gene expression) technology ... Expression profiles generated by SAGE ... low-abundance transcripts making it possible ... I-SAGE Kit is designed to ...
    The Captivate Disposable Sample Chamber is designed for use with the Captivate magnetic yoke assembly (C-24700) and can be used with our Captivate ferrofluid conjugates (C-21473 C-21474 C-21476) or ...
    Biology Products: